GALT GALECTIN THERAPEUTICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1133416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY37.8%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-179.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets357.0%
Debt / equity—
Current ratio0.28x
Interest coverage-2.20x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-66.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $14.29M | $36.57M | $32.13M | $31.74M | $23.82M |
| SG&A expense | $5.79M | $5.86M | $5.94M | $6.62M | $6.36M |
| Operating income | -$20.09M | -$42.43M | -$38.07M | -$38.35M | -$30.18M |
| Interest expense | $7.33M | $5.54M | $2.79M | $1.03M | $489,000 |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | -$30.53M |
| EBITDA | — | -$42.43M | -$38.07M | -$38.35M | -$30.18M |
| EPS (basic) | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 |
| EPS (diluted) | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 |
| Weighted avg. shares (diluted) | 63.90M | 62.31M | 60.16M | 59.39M | 58.53M |
| Balance sheet | |||||
| Cash & equivalents | $17.72M | $15.12M | $25.66M | $18.59M | $39.65M |
| Current assets | $19.44M | $17.25M | $27.71M | $20.55M | $41.82M |
| PP&E, net | $0 | $0 | $0 | $0 | $0 |
| Total assets | $19.53M | $17.50M | $28.20M | $21.29M | $41.83M |
| Current liabilities | $8.03M | $35.41M | $15.68M | $13.01M | $9.03M |
| Total liabilities | $145.73M | $120.56M | $88.44M | $53.48M | $39.21M |
| Shareholders' equity | -$127.92M | -$104.79M | -$61.96M | -$33.92M | $893,000 |
| Shares outstanding | 65.20M | 63.16M | 61.85M | 59.43M | 59.34M |
| Cash flow statement | |||||
| Operating cash flow | -$23.88M | -$41.77M | -$32.97M | -$31.06M | -$24.31M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $26.48M | $31.23M | $40.03M | $10.00M | $36.81M |
| Depreciation & amortization | — | $0 | $0 | $0 | $0 |
| Stock-based compensation | $1.66M | $2.45M | $2.26M | $2.87M | $2.08M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.